Statistics from Altmetric.com
Well-designed clinical trial extension studies (TES) can provide robust and meaningful information on the long-term safety, tolerability and efficacy of emergent drugs. A previous 'European Alliance of Associations for Rheumatology (EULAR) initiative established recommendations on the conduct, design and analysis of TES to mitigate potential bias and distortion of long-term outcomes,1 which subsequent post-randomised controlled trial (RCT) TES have applied. As prior participants to this initiative, we highlight an area that needs further consideration, namely the selection of the control group that takes place to switch to experimental therapy.
The objective of TES is to capture outcomes of patients exposed to the experimental drug. The recommendations emphasise the importance of intention-to-treat (ITT) analysis, the denominator being the original number entering the RCT. In the original trial, the purpose of ITT is to capture outcomes for the complete randomised population, regardless of exposure to the intervention, as we …
Handling editor Josef S Smolen
Contributors MHB drafted and WPM and MB revised the manuscript. All authors approved the final submitted manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Disclaimer MHB: The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.